title: Comparison of a commercial Varicella Zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and post vOka vaccination sera from healthcare workers.
abstract: BACKGROUND
  Recently, a commercial, standardised VZV IgG glycoprotein EIA, Binding Site VaccZyme™VZV glycoprotein IgG low level EIA (VaccZyme™EIA) has become available. The VaccZyme™EIA is more robust and user friendly than the reference VZV time-resolved fluorescence immunoassay (VZV TRFIA).
  
  
  OBJECTIVE
  To assess the usefulness of the VaccZyme™EIA in the diagnostic laboratory by comparing VZV IgG levels generated by both assays on serum panels representing, non-vaccinated, and vOka vaccinated populations.
  
  
  METHODS
  Sera from non-vaccinated individuals were tested; 248 from pregnant women, 117 from various patient groups referred to the Virus Reference Department for confirmatory VZV IgG testing and 102 from healthcare workers enrolled in a study (ROVE) of antibody/IgG response to vOka. From the ROVE study, 282 post vaccination sera were tested; 108 and 101 collected at six weeks post first and second doses of vOka, respectively, and 73 collected at 18 month follow-up.
  
  
  RESULTS
  Sensitivities and specificities (equivocals treated as negatives) of the VaccZyme™EIA for sera from pregnant women were 97.8% (95% CI: [94.6%, 99.4%]) and 96.8% (95% CI: [89.0%, 99.6%]), respectively, and for sera referred for confirmatory testing were 81.2% (95% CI: [71.2%, 88.8%]) and 96.9% (95% CI: [83.8%, 99.9%]), respectively, and for ROVE baseline sera were 54.2% (95% CI: [32.8%, 74.4%]) and 100% (95% CI: [95.4%, 100.0%]), respectively. For the post vOka serum panels sensitivities of the VaccZyme™EIA ranged from 65.3% (95% CI: [50.4%, 78.3%]) to 80.4% (95% CI: [71.1%, 87.8%]). Specificities were all 100%. Correlation with VZV TRFIA was high and agreement varied between the serum panels tested.
  
  
  CONCLUSIONS
  VaccZyme™EIA is recommended for detecting VZV IgG in sera from non-vaccinated populations; however, caution is advised when measuring post vOka VZV IgG levels.
authors.affiliation: Virus Reference Department, Health Protection Agency, Microbiology Services, Colindale, London, UK. chris.maple@hpa.org.uk
authors.forename: P A C
authors.initials: PA
authors.lastname: Maple
authors.forename: J
authors.initials: J
authors.lastname: Breuer
authors.forename: M
authors.initials: M
authors.lastname: Quinlivan
authors.forename: G
authors.initials: G
authors.lastname: Kafatos
authors.forename: K E
authors.initials: KE
authors.lastname: Brown
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D002644:Chickenpox / Q000175:diagnosis / Q000276:immunology; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D015200:Fluoroimmunoassay / Q000379:methods*; D006282:Health Personnel; D006562:Herpes Zoster / Q000175:diagnosis / Q000276:immunology; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood*; D011247:Pregnancy; D012044:Regression Analysis; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D007074:Immunoglobulin G; D014759:Viral Envelope Proteins